Michael Lee

Executive Director, Research Resource Program
Vice Chanc Research
+1 415 430-7676

Michael joined the Research Resource Program (RRP) team in 2018 and currently serves as Executive Director. His goal is to support the development, implementation and support of programs that will have a broad impact across UCSF Core & Shared Resource Facilities and enhance UCSF research capabilities. By working with the broad stake holders to maintain communication channels and build bridges, the RRP team contributes to the success of UCSF cores and shared resources.     

Michael has been at UCSF since 2003, working in labs and Cores where he became increasingly engaged in meeting general challenges faced by the research community. He has also led and worked with individual Cores to improve their operations and has coordinated funding for much needed instrumentation and operational support. Previously, he was the Director for the Parnassus Flow Cytometry (PFCC) and Monoclonal Antibody Cores and continues to advise both Cores. He also is a member of the Bluestone lab, working on the development and continuation of clinical trials involving the use of Regulatory T cells (Tregs) for the treatment of various ailments such as Type-1 diabetes.

Michael has a BA in Biology from UC Santa Cruz and an MS in Biomedical Laboratory Sciences from San Francisco State.


Reprogramming human T cell function and specificity with non-viral genome targeting.


Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Science translational medicine

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

Journal of immunology (Baltimore, Md. : 1950)

McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

PloS one

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA

Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease.


Szot GL, Lee MR, Tavakol MM, Lang J, Dekovic F, Kerlan RK, Stock PG, Posselt AM

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.

Journal of immunology (Baltimore, Md. : 1950)

Esensten JH, Lee MR, Glimcher LH, Bluestone JA

Expansion of human regulatory T-cells from patients with type 1 diabetes.


Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.

Proceedings of the National Academy of Sciences of the United States of America

Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

The Journal of experimental medicine

Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA